Target intelligence / Profile preview

Erwinia amylovora (E. amylovora)

Target
E. amylovora
Molecular classification
Gram-negative bacterium, Erwiniaceae family, Gammaproteobacteria, Plant pathogen
01

Overview

Erwinia amylovora is a Gram-negative phytopathogenic bacterium and the etiological agent of fire blight, a highly destructive disease affecting pome fruit trees such as Malus (apple) and Pyrus (pear) [1, 2]. It is characterized by its ability to rapidly colonize plant tissues, leading to necrosis and a scorched appearance of blossoms, leaves, and twigs [2]. The primary virulence factors include the Type III secretion system (T3SS), which translocates DspA/E effectors to suppress host hypersensitive responses, and the synthesis of the exopolysaccharide amylovoran, which facilitates vascular plugging and biofilm development [3]. While traditionally managed with antibiotics like streptomycin and kasugamycin, the emergence of resistant strains has shifted focus toward developing small-molecule inhibitors of T3SS or amylovoran biosynthesis [4, 5]. Understanding the molecular mechanisms of E. amylovora is critical for developing targeted agricultural therapeutics that mitigate crop loss without promoting broad-spectrum environmental resistance [5].

Other names
Fire blight bacteriumMicrococcus amylovorusBacillus amylovorus
02

Mechanism of action

The primary mechanisms of action for agents targeting Erwinia amylovora involve the inhibition of bacterial protein synthesis; streptomycin and kasugamycin bind to the 30S ribosomal subunit, while oxytetracycline binds to the 30S/50S subunits to prevent aminoacyl-tRNA attachment [4]. Copper-based bactericides act through the non-specific denaturation of proteins and disruption of cellular membranes [2]. Additionally, growth regulators like prohexadione-calcium act indirectly by inhibiting the biosynthesis of gibberellins, which alters host physiology to reduce the spread of the infection [5].

03

Biological functions

PathogenesisType III protein secretionExopolysaccharide (amylovoran) biosynthesisBiofilm formationIron acquisition (siderophores)
04

Disease associations

Fire blightPlant infection
05

Safety considerations

Development of antibiotic-resistant strains (e.g., streptomycin resistance)Phytotoxicity to host plants at high concentrationsEnvironmental accumulation of copper and toxicity to aquatic lifeDisruption of beneficial microbial flora in the orchard ecosystem
06

Interacting drugs

Streptomycin

4 more in the full profile.

07

Biomarkers

Presence of the pEA29 plasmidExpression of hrp (hypersensitive response and pathogenicity) genesDetection of ams (amylovoran synthesis) gene clustersVisual symptoms of 'shepherd's crook' in infected shoots

Beyond the preview

Go deeper on Erwinia amylovora (E. amylovora).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Erwinia amylovora (E. amylovora).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call